Cord blood cells for transfusion in extremely premature babies
Part of Blood & lymphatic, Eyes & vision, Genetic & congenital, Lungs & breathing, Women’s health & pregnancy clinical trials.
This study tests whether red blood cells made from donated cord blood are safe and effective for very premature babies who need a transfusion. It may offer an alternative to standard donor blood for these fragile infants.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Baby is born before 28 weeks of pregnancy or weighs less than 1000 grams at birth.
- The baby is admitted to a participating neonatal intensive care unit (NICU) in the Barcelona area.
- Parents or legal guardians must sign a consent form.
- Baby has not had any red blood cell transfusions before joining the study.
- The baby does not have certain medical conditions like severe birth defects, infections, or fluid buildup (hydrops).
- The baby is not in immediate need of blood transfusion at the time of joining the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how red blood cell transfusions affect health problems in babies born before 32 weeks of pregnancy. It may help doctors understand if transfusions are linked to complications of prematurity.
This study looks at microscopic particles called extracellular vesicles in the umbilical cord blood of babies born before 28 weeks. Researchers want to see if these particles can help predict severe health problems or death, and eventually improve care for extremely premature newborns.
This trial tests whether giving stem cells to very premature babies can help prevent bronchopulmonary dysplasia, a lung condition that often affects babies born before 28 weeks. The stem cells are given through an IV, and the study compares them to a placebo to see if they improve lung health.
This study looks at vitamin A levels in cord blood (blood from the umbilical cord after birth) and how they relate to health outcomes for babies born very early (before 32 weeks). Participating may help researchers understand if vitamin A affects prematurity complications.
This study tests whether using cord blood (the blood left in the umbilical cord after birth) that is rich in fetal hemoglobin (the type of hemoglobin babies have before birth) can make blood transfusions safer and more personalized for very premature babies. If this works, it might reduce the need for multiple transfusions and improve outcomes for preterm infants.
This trial tests different ways of transferring blood from the umbilical cord to very premature babies (born at or before 32 weeks) to see if it can prevent complications of prematurity and improve their blood counts. It aims to find the best method for helping these vulnerable newborns.
Hear when a new Extremely Premature Infant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.